Transient renin-angiotensin system stimulation in an early stage of life causes sustained hypertension in rats

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2369-2380

  Heijnen, Bart F J ^a   Peutz Kootstra, Carine J ^a   Mullins, John J ^b   Janssen, Ben J A ^a   Struijker Boudier, Harry A J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

(pre)hypertension; cyp1a1 Ren2 rat; renal damage; renal inflammation; renin angiotensin system; transient renin angiotensin system stimulation

Indexed keywords

CREATININE; CYTOCHROME P450 1A1; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RENIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET; FOLLOW UP; GLOMERULOSCLEROSIS; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRUCTURE ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 81355127249     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834cfcf4     Document Type: Article

References (31)

1. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52:639-672.
2. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
3. Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, et al. The PHARAO study: prevention of hypertension with the angiotensinconverting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German hypertension league. J Hypertens 2008; 26:1487-1496.
4. Baumann M, Hermans JJ, Janssen BJ, Peutz-Kootstra C, Witzke O, Heemann U, et al. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. J Hypertens 2007; 25:2504-2511.
5. Baumann M, Janssen BJ, Hermans JJ, Peutz-Kootstra C, Witzke O, Smits JF, Struijker Boudier HA. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 2007; 25:207-215.
6. Baumann M, Megens R, Bartholome R, Dolff S, van Zandvoort MA, Smits JF, et al. Prehypertensive renin-angiotensin-aldosterone systemblockade in spontaneously hypertensive rats ameliorates the loss of long-term vascular function. Hypertens Res 2007; 30:853-861.
7. Berecek KH, Nagahama S, Oparil S. Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat. J Hypertens Suppl 1984; 2:S63-S66.
8. Bergstrom G, Johansson I, Wickman A, Gan L, Thorup C. Brief losartan treatment in young spontaneously hypertensive rats abates long-termblood pressure elevation by effects on renal vascular structure. J Hypertens 2002; 20:1413-1421.
9. Harrap SB, Mirakian C, Datodi SR, Lever AF. Blood pressure and lifespan following brief ace inhibitor treatment in young spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1994; 21:125-127.
10. Baumann M, Bartholome R, Peutz-Kootstra CJ, Smits JF, Struijker-Boudier HA. Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging? Am J Hypertens 2008; 21:177-182.
11. Baumann M, Janssen BJ, Rob Hermans JJ, Bartholome R, Smits JF, Struijker Boudier HA. Renal medullary effects of transient prehypertensive treatment in young spontaneously hypertensive rats. Acta Physiol (Oxf) 2009; 196:231-237.
12. Chen Y, Lasaitiene D, Friberg P. The renin-angiotensin system in kidney development. Acta Physiol Scand 2004; 181:529-535.
13. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 2001; 276:36727-36733.
14. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 2006; 7:74-86.
15. Peters B, Grisk O, Becher B, Wanka H, Kuttler B, Ludemann J, et al. Dosedependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008; 26:102-109.
16. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29:367-374.
17. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006; 47:467-474.
18. Mengel M, Reeve J, Bunnag S, Einecke G, Jhangri GS, Sis B, et al. Scoring total inflammation is superior to the current BANFF inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9:1859-1867.
19. Damoiseaux JG, Dopp EA, Calame W, Chao D, MacPherson GG, Dijkstra CD. Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. Immunology 1994; 83:140-147.
20. Huskova Z, Vanourkova Z, Erbanova M, Thumova M, Opocensky M, Mullins JJ, et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-ren-2 transgenic rats. J Hypertens 2010; 28:495-509.
21. Howard CG, Mullins JJ, Mitchell KD. Transient induction of Ang II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to Ang II in Cyp1a1-ren2 transgenic rats. Am J Med Sci 2010; 339:543-548.
22. Howard CG, Mullins JJ, Mitchell KD. Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-ren2 transgenic rats with inducible angiotensin II-dependent malignant hypertension. Am J Med Sci 2011; 341:383-387.
23. Patterson ME, Mullins JJ, Mitchell KD. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 2008; 294:F205-211
24. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58:2425-2436.
25. Graciano ML, Mouton CR, Patterson ME, Seth DM, Mullins JJ, Mitchell KD. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. Am J Physiol Renal Physiol 2007; 292:F1858-F1866.
26. Opay AL, Mouton CR, Mullins JJ, Mitchell KD. Cyclooxygenase-2 inhibition normalizes arterial blood pressure in Cyp1a1-ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. Am J Physiol Renal Physiol 2006; 291:F612-F618.
27. Mitchell KD, Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. Am J Physiol Renal Physiol 2005; 289:F1210-F1216.
28. Vanourkova Z, Kramer HJ, Huskova Z, Vaneckova I, Opocensky M, Chabova VC, et al. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organdamage inCyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 2006; 24:2465-2472.
29. Williams DE, Prieto MC, Mullins JJ, Navar LG, Mitchell KD. AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet. Am J Med Sci 2010; 339:356-361.
30. Sanz-Rosa D, Oubina MP, Cediel E, de Las Heras N, Vegazo O, Jimenez J, et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol 2005; 288:H111-H115.
31. Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26:381-391.